Pulmonary hypertension in sickle cell disease

Clinical Advances in Hematology and Oncology

Volumn 5, Issue 8, 2007, Pages

  Lee, Margaret L ^a   Rosenzweig, Erika Berman ^a   Cairo, Mitchell S ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Hemolysis; Pulmonary hypertension; Sickle cell disease; Tricuspid regurgitant velocity

Indexed keywords

ADENOSINE; ANTIBIOTIC AGENT; ARGINASE; ARGININE; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; HEMOGLOBIN S; HYDROXYUREA; ILOPROST; IRON CHELATING AGENT; NITRIC OXIDE; OXYGEN; PROSTACYCLIN; SILDENAFIL; UNIPROST; VASODILATOR AGENT;

ANEMIA; ARTHRALGIA; ARTICLE; ASPLENIA; BACTERIAL INFECTION; BLOOD TRANSFUSION; CHRONIC LUNG DISEASE; CLINICAL FEATURE; CONTINUOUS INFUSION; COUGHING; DEATH; DIARRHEA; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DYSPEPSIA; EDEMA; EPISTAXIS; ERYTHROCYTE TRANSFUSION; FACE PAIN; FLUSHING; FUNCTIONAL ASSESSMENT; HEART CATHETERIZATION; HEART FAILURE; HEMOLYSIS; HUMAN; HYPOTENSION; HYPOXEMIA; INFECTION; INJECTION SITE PAIN; INJECTION SITE REACTION; IRON OVERLOAD; LABORATORY DIAGNOSIS; LIVER TOXICITY; LUNG ARTERY PRESSURE; LUNG FUNCTION TEST; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MORTALITY; NAUSEA; NONHUMAN; OXYGEN THERAPY; PATHOGENESIS; PREVALENCE; PRIAPISM; PRIMARY PREVENTION; PROGNOSIS; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RISK FACTOR; SCREENING TEST; SICKLE CELL ANEMIA; SIDE EFFECT; SINUS CONGESTION; STROKE; SURVIVAL RATE; THROMBOSIS;

ANEMIA, SICKLE CELL; HUMANS; HYPERTENSION, PULMONARY;

EID: 34848825033     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Sickle-cell anemia: Who is at risk? Available at http:// www.nhlbi.nih.gov/ health/dci/Diseases/Sca/SCA-WhoIsAtRisk.html. Accessed July 22, 2007.
2. Diggs L. Anatomic lesions in sickle cell disease. In: Abramson H, Bertles J, Wethers D, eds. Sickle Cell Disease: Diagnosis, Management, Education and Research. St. Louis: CV Mosby; 1973:189-229.
3. National Heart Lung and Blood Institute, Sickle Cell research for treatment and cure. NIH Publication. Bethesda, MD; 2002:02-5214.
4. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639-1644.
5. Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. Blood. 2004;103:4023-4027.
6. Powars D, Weidman J, Odom-Maryon T, et al. Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure. Medicine. 1988;67:66-76.
7. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289:1645-1651.
8. Koumbourlis AC, Zar HJ, Hurlet-Jensen A, Goldberg MR. Prevalence and reversibility of lower airway obstruction in children with sickle cell disease. J Pediatr. 2001;138:188-192.
9. Pianosi P, D'Souza SJ, Charge TD, et al. Pulmonary function abnormalities in childhood sickle cell disease. J Pediatr. 1993;122:366-371.
10. O Siddiqui AK, Ahmed S. Pulmonary manifestations of sickle cell disease. Postgrad Med. J 2003;79:384-390.
11. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350: 886-895.
12. Haque AK, Gokhale S, Rampy BA, et al. Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum Pathol. 2002; 33:1037-1043.
13. Castro O. Systemic fat embolism and pulmonary hypertension in sickle cell disease. Hematol Oncol Clin North Am. 1996;10:1289-1303.
14. Sutton LL, Castro O, Cross DJ, et al. Pulmonary hypertension in sickle cell disease. Am J Cardiol. 1994;74:626-628.
15. Araga KI, Seed N, De Gent G, et al. Pulmonary hypertension in sickle cell disease. Am J Med. 2004:117:665-669.
16. Ambrusko SJ, Gunawardena S, Sakara A, et al. Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease. Pediatr Blood Cancer. 2006;47:907-913.
17. Lee M, Khan A, Small T. et al. Prevalence and potential risk factors of pulmonary hypertension in children and adolescents with sickle cell disease [abstract]. Presented at the 29th Annual Meeting of the National Sickle Cell Disease Program. Memphis, TN; April 8-12, 2006.
18. Qureshi N, Joyce JJ, Qi N, Chang RK, Right ventricular abnormalities in sickle cell anemia: evidence of a progressive increase in pulmonary vascular resistance. J Pediatr. 2006; 149:23-27
19. Suell MN, Bezold LI, Okcu ME et al. Increased pulmonary artery pressures among adolescents with sickle cell disease. J Pediatr Hematol Oncol. 2005;27: 654-658
20. Machado RF, Gladwin MT. Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension. Br J Haematol. 2005;129:449-464.
21. Castro O, Hoque M, Brown BD, Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood. 2003;101:1257-1261.
22. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293:1653-1662.
23. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8:1383-1389.
24. Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA. 2005;294:81-90.
25. Gladwin MT Kato GJ. Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia. Hematol (Am Soc Hematol Educ Program). 2005:51-57.
26. Ergul S, Brunson CY, Hutchinson J, et al. Vasoactive factors in sickle cell disease: in vitro evidence for endothelin-l-mediated vasoconstriction. Am J Hematol. 2004;76:245-251.
27. Graido-Gonzalez E, Doherty JC, Rergreen EW, et al. Plasma endothelin-l, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis. Blood. 1998;92:2551-2555.
28. De Castro L, Jonassaint J, Telen M. Cardiac complications of sickle cell disease: correlation between the left and right side of the heart and association with pulmonary hypertension [abstractl. Presented at the 29th Annual Meeting of the National Sickle Cell Disease Program. Memphis, TN; April 8-12, 2006.
29. Ataga KI, Orringer EP. Hypercoagulability in sickle cell disease: a curious paradox. Am J Med. 2003;115:721-728.
30. Adedeji MO, Cespedes J, Allen K, et al. Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Arch Pathol Lab Med. 2001;25:1436-1441.
31. Yung GL, Channick RN, Fedullo PF, et al. Successful pulmonary thrombo-endarterectomy in two patients with sickle cell disease. Am J Respir Crit Care Med. 1998;157:1690-1693.
32. Castele RJ, Strohl KP, Chester CS, et al. Oxygen saturation with sleep in patients with sickle cell disease. Arch Intern Med. 1986; 146:722-725.
33. Needleman JP, Franco ME, Varlotta L, et al. Mechanisms of nocturnal oxyhemoglobin desaturation in children and adolescents with sickle cell disease. Pediatr Pulmonol. 1999;28:418-422.
34. Hargrave DR, Wade A, Evans JP, et al. Nocturnal oxygen saturation and painful sickle cell crises in children. Blood. 2003; 101:846-848.
35. Kirkham FJ, Hewes DK, Prengler M, et al. Nocturnal hypoxaemia and central-nervous-system events in sickle-cell disease. Lancet. 2001;357:1656-1659.
36. Neumayr L, Morris C, Harmatz P, et al. Pulmonary hypertension in chronically transfused patients with sickle cell and thalassemia: a report from the multi-center study of iron overload [abstract]. Presented at the 29th Annual Meeting of the National Sickle Cell Disease Program. Memphis, TN; April 8-12, 2006.
37. Kato GJ, McGowan V, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood. 2006;107:2279-2285.
38. Kato GJ, Hsieh M, Machado R, et al. Cerebrovascular disease associated with sickle cell pulmonary hypertension. Am J Hematol. 2006;81:503-510.
39. Nolan VG, Wyszynski DF, Fatter LA, Steinberg MH. Hemolysis-associated priapism in sickle cell disease. Blood. 2005; 106:3264-3267.
40. Morris CR, Gardner J, Hagar W, et al. Pulmonary hypertension in sickle cell disease: a common complication for both adults and children [abstract]. Presented at the 27th Annual Meeting of the National Sickle Cell Disease Program. Los Angeles, CA; April 18-21, 2004.
41. Castro O, Gladwin MT. Pulmonary hypertension in sickle cell disease: mechanisms, diagnosis, and management. Hematol Oncol Clin North Am. 2005;19: 881-896.
42. Klings ES, Farber HW. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease [author reply]. N Engl J Med. 2004;350: 2521-2522.
43. Machado RF, Martyr SE, Anthi A, et al. Pulmonary hypertension in sickle cell disease: cardiopulmonary evaluation and response to chronic phosphodiesterase 5 inhibitor therapy [abstract]. Blood. 2004;104:71a.
44. Machado RF, Kyle Mack A, Martyr S, et al. Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell disease. Br J Haematol. 2007; 136:319-325
45. Currie PJ, Seward JB, Chan KL, et al. Continuous wave Doppler determination of right venctricular pressure: a simultaneous Doppler-cathererization study in 127 patients. J Am Coll Cardiol. 1985;6:750-756.
46. Ataga KI, Moore CG, Jones S, et al. Pulmonar - hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol. 2006;134:109-115.
47. Sickle cell disea.se in children and adolescents: diagnosis, guidelines for comprehensive care, and acute care paths and protocols for management of acute and chronic complications. (for the Sickle Cell Disease Consortium). Sickle Cell Disease Consortium. 2001. Available at: http://www.scinfo.org/protchildindex.htm. Acceessed July 22, 2007.
48. American Academy of Pediatrics, Section of Hematology/Oncology and Committee on Genetics. Health supervision for children with sickle cell disease. Pediatrics. 2002;109:526-535.
49. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:40S-47S.
50. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation. 2006; 114:1417-1431.
51. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332:1317-1322.
52. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood. 1999;94:1550-1554.
53. Steinberg MH. Pathophysiologically based drug treatment of sickle cell disease. Trends Pharmacol Sci. 2006;27:204-210.
54. Cokic VP, Smith RD, Beleslin-Cokic BB, et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest. 2003; 111:231-239.
55. Nahavandi M, Wyche MQ, Perlin E, et al. Nitric oxide metabolites in sickle cell anemia patients after oral administration of hydroxyurea; hemoglobinopathy. Hematology. 2000;5:335-339.
56. Pacelli R, Taira J, Cook JA, et al. Hydroxyurea reacts with heme proteins to generate nitric oxide. Lancet. 1996;347:900.
57. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339:5-11.
58. Pegelow CH, Adams RJ, McKie V, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr. 1995;126:896-899.
59. Miller ST, Macklin EA, Pegelow CH, et al. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. J Pediatr. 2001;139:385-390.
60. Wang WC, Morales KH, Scher CD, et al. Effect of lon-term transfusion on growth in children with sickle cell anemia: results of the STOP trial. J Pediatr. 2005;147:244-247.
61. Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353:2769-2778.
62. Sakhalkar VS, Rao SP, Weedon J, Miller ST. Elevated plasma sVCAM-1 levels in children with sickle cell disease: impact of chronic transfusion therapy. Am J Hematol. 2004;76:57-60.
63. Frank H, Mlczoch J, Huber K, et al. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest. 1997;112: 714-721.
64. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984;70:580-587.
65. Weiss BM, Zemp L, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol. 1998;31:1650-1657.
66. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:35S-62S.
67. Lee SH, Rubin LJ. Current treatment strategies for pulmonary arterial hypertension. J Intern Med. 2005;258:199-215.
68. Machado RF, Martyr S, Kato GJ, et al. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol. 2005; 130:445-453.
69. Morris CR, Morris SM, Jr., Hagar W, et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med. 2003;169:63-69.
70. Nelson SC, Adabe BB, McDonough EA, et al. High prevalence of pulmonary hypertension in children with sickle cell disease. J Pediatr Hematol Oncol. 2007;29:334-347.
71. Hsu LL, Champion HC, Campbell-Lee SA, et al. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood. 2007;109:3088-3098.